» Articles » PMID: 35768113

Fluoxetine for Reducing Postoperative Cognitive Dysfunction in Elderly Patients After Total Knee Replacement: Study Protocol for a Single-centre, Double-blind, Randomised, Parallel-group, Superiority, Placebo-controlled Trial

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 Jun 29
PMID 35768113
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Postoperative cognitive dysfunction (POCD) is a common complication following major surgical procedures. The underlying pathophysiology is poorly understood, but the role of neuroinflammation is strongly implicated. Given the antineuroinflammatory and neuroprotective effects of fluoxetine, we hypothesise that fluoxetine may reduce the cumulative incidence of POCD in elderly patients undergoing total knee arthroplasty (TKA).

Methods And Analysis: This is a prospective, randomised, double-blind, parallel-group, placebo-controlled, superiority trial. Five hundred elderly patients undergoing unilateral TKA will be randomly assigned to the fluoxetine and placebo groups. The fluoxetine group will receive fluoxetine 20 mg daily 8 weeks preoperatively, and the placebo group will receive placebo capsules daily 8 weeks preoperatively. The primary outcome is the cumulative incidence of POCD at 1 month postoperatively. The secondary outcomes include the occurrence of delirium, the area under the curve of the Numeric Rating Scale pain scores over time, and sleep disturbance. Data on all the results, risk factors and adverse events will also be collected and analysed.

Ethics And Dissemination: The Fujian Provincial Hospital Ethics Board has approved the protocol for this trial (identifier number: K2021-01-009). All participants will be required to provide written informed consent before any protocol-specific procedures.

Trial Registration Number: ChiCTR2100050424.

Citing Articles

The multifaceted effects of fluoxetine treatment on cognitive functions.

Ampuero E, Luarte A, Flores F, Soto A, Pino C, Silva V Front Pharmacol. 2024; 15:1412420.

PMID: 39081952 PMC: 11286485. DOI: 10.3389/fphar.2024.1412420.


Preoperative mild cognitive impairment as a risk factor of postoperative cognitive dysfunction in elderly patients undergoing spine surgery.

Park S, Kim J, Ha Y, Kim K, Yi S, Koo B Front Aging Neurosci. 2024; 16:1292942.

PMID: 38282693 PMC: 10811182. DOI: 10.3389/fnagi.2024.1292942.


Fluoxetine alleviates postoperative cognitive dysfunction by attenuating TLR4/MyD88/NF-κB signaling pathway activation in aged mice.

Yao Y, Lin D, Chen Y, Liu L, Wu Y, Zheng X Inflamm Res. 2023; 72(6):1161-1173.

PMID: 37188940 DOI: 10.1007/s00011-023-01738-8.

References
1.
Yue T, Li Q, Wang R, Liu Z, Guo M, Bai F . Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis. Dermatology. 2019; 236(2):170-178. DOI: 10.1159/000498848. View

2.
Mowla A, Mosavinasab M, Pani A . Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007; 27(1):67-70. DOI: 10.1097/JCP.0b013e31802e0002. View

3.
Ren S, Yuan F, Yuan S, Zang C, Zhang Y, Lang B . Early Cognitive Dysfunction in Elderly Patients after Total Knee Arthroplasty: An Analysis of Risk Factors and Cognitive Functional Levels. Biomed Res Int. 2022; 2022:5372603. PMC: 8881138. DOI: 10.1155/2022/5372603. View

4.
Lim C, Kim S, Park J, Kim C, Yoon S, Lee J . Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2008; 87(4):1037-45. DOI: 10.1002/jnr.21899. View

5.
Chollet F, Tardy J, Albucher J, Thalamas C, Berard E, Lamy C . Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; 10(2):123-30. DOI: 10.1016/S1474-4422(10)70314-8. View